Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vopratelimab Rollover Study
NCT04319224Phase 2Terminated
- Sponsor
- Jounce Therapeutics
- Start
- Mar 2020
- Primary completion
- Jan 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of vopratelimab in solid tumor, sponsored by Jounce Therapeutics. Started Mar 2020; status: terminated.
02
Drugs
vopratelimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04319224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04319224.